Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel syndrome: A systematic review and meta-analysis

Nutrition

Volumn 45, Issue , 2018, Pages 24-31

  Schumann, Dania ^a   Klose, Petra ^a   Lauche, Romy ^a,b   Dobos, Gustav ^a   Langhorst, Jost ^a   Cramer, Holger ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

FODMAP diet; Gut microbiota; Irritable bowel syndrome; Meta analysis

Indexed keywords

DISACCHARIDE; MONOSACCHARIDE; OLIGOSACCHARIDE; POLYOL; PROBIOTIC AGENT; POLYMER;

ABDOMINAL PAIN; ADVERSE OUTCOME; ANXIETY; ARTICLE; BIFIDOBACTERIUM; CLINICAL OUTCOME; DEPRESSION; DIET THERAPY; DISEASE SEVERITY; FEEDING BEHAVIOR; FERMENTATION; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE FLORA; IRRITABLE COLON; META ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDIZATION; SYMPTOM; SYSTEMATIC REVIEW; THERAPY EFFECT; WESTERN DIET; CHEMISTRY; GASTROINTESTINAL TRACT; LOW CARBOHYDRATE DIET; METABOLISM; MICROBIOLOGY;

ABDOMINAL PAIN; DIET, CARBOHYDRATE-RESTRICTED; DISACCHARIDES; FERMENTATION; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME; MONOSACCHARIDES; OLIGOSACCHARIDES; POLYMERS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85033698090     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2017.07.004     Document Type: Article

References (40)

1. Canavan, C., West, J., Card, T., The epidemiology of irritable bowel syndrome. Clin Epidemiol, 6, 2014, 71.
2. Drossman, D.A., Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV. Gastroenterology 150 (2016), 1262–1279.
3. Eswaran, S., Tack, J., Chey, W.D., Food: The forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am 40 (2011), 141–162.
4. Barrett, J.S., Gearry, R.B., Muir, J.G., Irving, P.M., Rose, R., Rosella, O., et al. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther 31 (2010), 874–882.
5. Halmos, E.P., Christophersen, C.T., Bird, A.R., Shepherd, S.J., Gibson, P.R., Muir, J.G., Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64 (2015), 93–100.
6. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., The, P.G., Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med, 6, 2009, e1000097.
7. Cochrane Handbook for Systematic Reviews of interventions. Available at: http://training.cochrane.org/handbook. Accessed November 7, 2011.
8. Drossman, D.A., Dumitrascu, D.L., Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis 15 (2006), 237–241.
9. Francis, C.Y., Morris, J., Whorwell, P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11 (1997), 395–402.
10. Ware, J.E., Kosinski, M., Dewey, J.E., How to score Version 2 of the SF-36 Health Survey. 2000, QualityMetric Incorporated, Lincoln, RI.
11. Patrick, D.L., Drossman, D.A., Frederick, I.O., DiCesare, J., Puder, K.L., Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig Dis Sci 43 (1998), 400–411.
12. Zigmond, A.S., Snaith, R.P., The hospital anxiety and depression scale. Acta Psychiatr Scand 67 (1983), 361–370.
13. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
14. Biesiekierski, J.R., Peters, S.L., Newnham, E.D., Rosella, O., Muir, J.G., Gibson, P.R., No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 145 (2013), 320–328 e321–e323.
15. Bohn, L., Storsrud, S., Liljebo, T., Collin, L., Lindfors, P., Tornblom, H., et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial. Gastroenterology 149 (2015), 1399–1407 e1392.
16. Chumpitazi, B.P., Cope, J.L., Hollister, E.B., Tsai, C.M., McMeans, A.R., Luna, R.A., et al. Randomised clinical trial: Gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 42 (2015), 418–427.
17. Halmos, E.P., Power, V.A., Shepherd, S.J., Gibson, P.R., Muir, J.G., A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146 (2014), 67–75 e65.
18. McIntosh, K., Reed, D.E., Schneider, T., Dang, F., Keshteli, A.H., De Palma, G., et al. FODMAPs alter symptoms and the metabolome of patients with IBS: A randomised controlled trial. Gut 66 (2017), 1241–1251.
19. Pedersen, N., Andersen, N.N., Vegh, Z., Jensen, L., Ankersen, D.V., Felding, M., et al. Ehealth: Low FODMAP diet vs lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol 20 (2014), 16215–16226.
20. Staudacher, H.M., Lomer, M.C., Anderson, J.L., Barrett, J.S., Muir, J.G., Irving, P.M., et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 142 (2012), 1510–1518.
21. Staudacher, H.M., Lomer, M., Louis, P., Farquharson, F., Lindsay, J.O., Irving, P.M., et al. The low FODMAP diet reduces symptoms in irritable bowel syndrome compared with placebo diet and the microbiota alterations may be prevented by probiotic co-administration: A 2 x2 factorial randomized controlled trial. Gastroenterology, 150, 2016, S230.
22. Harvie, R., Schultz, M., Chisholm, A., A reduction in FODMAP intake correlates strongly with a reduction in IBS symptoms–the FIBS study. J Gastroenterol Hepatol 28 (2013), 623–693.
23. Eswaran, S.L., Chey, W.D., Han-Markey, T., Ball, S., Jackson, K., A randomized controlled trial Comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol 111 (2016), 1824–1832.
24. Ong, D.K., Mitchell, S.B., Barrett, J.S., Shepherd, S.J., Irving, P.M., Biesiekierski, J.R., et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 25 (2010), 1366–1373.
25. Gibson, P.R., Shepherd, S.J., Food choice as a key management strategy for functional gastrointestinal symptoms. Am J Gastroenterol 107 (2012), 657–666 quiz 667.
26. Eswaran, S., Muir, J., Chey, W.D., Fiber and functional gastrointestinal disorders. Am J Gastroenterol 108 (2013), 718–727.
27. Whitehead, W.E., Crowell, M.D., Robinson, J.C., Heller, B.R., Schuster, M.M., Effects of stressful life events on bowel symptoms: Subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 33 (1992), 825–830.
28. Cole, J.A., Rothman, K.J., Cabral, H.J., Zhang, Y., Farraye, F.A., Migraine, fibromyalgia, and depression among people with IBS: A prevalence study. BMC Gastroenterol, 6, 2006, 26.
29. Rao, A.V., Bested, A.C., Beaulne, T.M., Katzman, M.A., Iorio, C., Berardi, J.M., et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog, 1, 2009, 6.
30. Aizawa, E., Tsuji, H., Asahara, T., Takahashi, T., Teraishi, T., Yoshida, S., et al. Possible association of bifidobacterium and lactobacillus in the gut microbiota of patients with major depressive disorder. J Affect Disord 202 (2016), 254–257.
31. Whelan, K., Quigley, E.M., Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 29 (2013), 184–189.
32. Wang, H., Gong, J., Wang, W., Long, Y., Fu, X., Fu, Y., et al. Are there any different effects of bifidobacterium, lactobacillus and streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?. PLoS One, 9, 2014, e90153.
33. Kerckhoffs, A.P., Samsom, M., van der Rest, M.E., de Vogel, J., Knol, J., Ben-Amor, K., et al. Lower bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 15 (2009), 2887–2892.
34. Marsh, A., Eslick, E.M., Eslick, G.D., Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr 55 (2016), 897–906.
35. Mansueto, P., Seidita, A., D'Alcamo, A., Carroccio, A., Role of FODMAPs in patients with irritable bowel syndrome. Nutr Clin Pract 30 (2015), 665–682.
36. Kang, J.Y., Systematic review: The influence of geography and ethnicity in irritable bowel syndrome. Aliment Pharmacol Ther 21 (2005), 663–676.
37. Gartlehner, G., Assessment of adverse effects and applicability–two areas not (yet) covered adequately in Cochrane reports. Z Evid Fortbild Qual Gesundhwes 102 (2008), 497–502.
38. Wu, G.D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.Y., Keilbaugh, S.A., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334 (2011), 105–108.
39. Miller, L.E., Study design considerations for irritable bowel syndrome clinical trials. Ann Gastroenterol 27 (2014), 338–345.
40. Schulz, K.F., Altman, D.G., Moher, D., CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152 (2010), 726–732.